These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 19238933

  • 1. [Pneumology. Should we fear inhaled anticholinergic bronchodilators?].
    Rochat T, Janssens JP.
    Rev Med Suisse; 2009 Jan 14; 5(186):135-7. PubMed ID: 19238933
    [Abstract] [Full Text] [Related]

  • 2. Comparison of risk of neurovascular and cardiovascular side effects between tiotropium and other anticholinergic agents.
    Alzayer R, Hughes J, Parsons R, Lee YP.
    Qual Prim Care; 2010 Jan 14; 18(3):189-99. PubMed ID: 20659403
    [Abstract] [Full Text] [Related]

  • 3. A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD.
    Hilleman DE, Malesker MA, Morrow LE, Schuller D.
    Int J Chron Obstruct Pulmon Dis; 2009 Jan 14; 4():253-63. PubMed ID: 19657399
    [Abstract] [Full Text] [Related]

  • 4. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
    Baker WL, Baker EL, Coleman CI.
    Pharmacotherapy; 2009 Aug 14; 29(8):891-905. PubMed ID: 19637942
    [Abstract] [Full Text] [Related]

  • 5. Tiotropium: a bronchodilator for chronic obstructive pulmonary disease.
    Somand H, Remington TL.
    Ann Pharmacother; 2005 Sep 14; 39(9):1467-75. PubMed ID: 16030078
    [Abstract] [Full Text] [Related]

  • 6. Tiotropium: a potential replacement for ipratropium in patients with COPD.
    Shukla VK.
    Issues Emerg Health Technol; 2002 Jul 14; (35):1-4. PubMed ID: 12195603
    [Abstract] [Full Text] [Related]

  • 7. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.
    Chen AM, Bollmeier SG, Finnegan PM.
    Ann Pharmacother; 2008 Dec 14; 42(12):1832-42. PubMed ID: 18957624
    [Abstract] [Full Text] [Related]

  • 8. Use of inhaled anticholinergic agents in obstructive airway disease.
    Restrepo RD.
    Respir Care; 2007 Jul 14; 52(7):833-51. PubMed ID: 17594728
    [Abstract] [Full Text] [Related]

  • 9. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications.
    Singh S, Loke YK, Enright P, Furberg CD.
    Thorax; 2013 Jan 14; 68(1):114-6. PubMed ID: 22764216
    [Abstract] [Full Text] [Related]

  • 10. [Safety and tolerability of bronchodilators in chronic obstructive pulmonary disease].
    Sanjuás C.
    Arch Bronconeumol; 2009 Jan 14; 45 Suppl 5():21-6. PubMed ID: 20116758
    [Abstract] [Full Text] [Related]

  • 11. Republished: pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications.
    Singh S, Loke YK, Enright P, Furberg CD.
    Postgrad Med J; 2014 Apr 14; 90(1062):205-7. PubMed ID: 24643260
    [Abstract] [Full Text] [Related]

  • 12. [Are there cardiovascular adverse effects of inhaled anticholinergics?].
    Nagy LB.
    Orv Hetil; 2015 Aug 02; 156(31):1246-52. PubMed ID: 26211748
    [Abstract] [Full Text] [Related]

  • 13. The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease.
    Tashkin DP.
    Expert Opin Drug Saf; 2015 Aug 02; 14(11):1759-72. PubMed ID: 26401729
    [Abstract] [Full Text] [Related]

  • 14. Anticholinergic agents in asthma and COPD.
    Gross NJ.
    Eur J Pharmacol; 2006 Mar 08; 533(1-3):36-9. PubMed ID: 16488410
    [Abstract] [Full Text] [Related]

  • 15. Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease.
    Lee TA, Schumock GT, Bartle B, Pickard AS.
    Pharmacotherapy; 2009 Sep 08; 29(9):1039-53. PubMed ID: 19698009
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease.
    Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R, Stukel TA.
    JAMA Intern Med; 2013 Jul 08; 173(13):1175-85. PubMed ID: 23689820
    [Abstract] [Full Text] [Related]

  • 17. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidence.
    Salpeter SR.
    Drugs; 2009 Oct 22; 69(15):2025-33. PubMed ID: 19791824
    [Abstract] [Full Text] [Related]

  • 18. Inhaled anticholinergic drugs and risk of acute urinary retention.
    Afonso AS, Verhamme KM, Stricker BH, Sturkenboom MC, Brusselle GG.
    BJU Int; 2011 Apr 22; 107(8):1265-72. PubMed ID: 20880196
    [Abstract] [Full Text] [Related]

  • 19. [Drug therapies of COPD].
    Noseda A.
    Rev Med Brux; 2003 Sep 22; 24(4):A354-7. PubMed ID: 14606301
    [Abstract] [Full Text] [Related]

  • 20. The cardiovascular risk of tiotropium: is it real?
    Cazzola M, Calzetta L, Matera MG.
    Expert Opin Drug Saf; 2010 Sep 22; 9(5):783-92. PubMed ID: 20565229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.